Effects of Antifungal Treatment in COVID-19-Associated Pulmonary Aspergillosis: A European Multicenter Cohort Study
Authors' conclusion
Our results show that antifungal treatment was associated with lower 60-day mortality in patients with CAPA.
Study context
- Population
- Patients with probable or proven COVID-19-associated pulmonary aspergillosis (CAPA), French multicenter study and ICUs of 5 major European centers
- Participants
- 259 patients
- Exposure
- Antifungal treatment vs no antifungal treatment
- Antifungalsn = 237
- Outcome
- Mortality
- Follow-up
- 60 days
Methodological detailsinverse probability of treatment weighting based on a propensity score, Cox regression analysis
- Inverse probability of treatment weighting based on a propensity score
- Cox regression analysis
Main finding
As reported in the abstract
60-day mortality
Antifungals vs No antifungalsEstimate (95% CI)P value
Cox-weighted regression
weighted HR 0.28(0.13–0.58)
P < 0.001Cox regression, raw population
HR 0.31(0.17–0.59)
P < 0.001Observational data: associations, not effects.
Further findings
Other factors associated with 60-day mortality (Cox regression, raw population)
- Age, HR
- 1.02 (95% CI 1.00-1.04; P = .048)
- Immunosuppressive treatment, HR
- 2.08 (95% CI 1.12-3.41; P < .001)
- Remdesivir administration, HR
- 1.96 (95% CI 1.12-3.41; P = .018)
- Male sex, HR
- 0.61 (95% CI 0.40-0.95; P = .024)
Original publication
Effects of Antifungal Treatment in COVID-19-Associated Pulmonary Aspergillosis: A European Multicenter Cohort Study. Chest. Published 17 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →